Chronic Kidney Disease (CKD) Clinical Trial
Official title:
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia
The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium). The study also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer treatment was also evaluated.
There were two parts in the study, Part A and Part B. Part A was an assessment of 4 weeks of dosing with patiromer in the treatment of hyperkalemia; Part B was a randomized, placebo-controlled, 8-week assessment of the withdrawal of patiromer in participants with a baseline serum potassium at the beginning of Part A ≥ 5.5 mEq/L who responded to the 4 weeks of treatment with patiromer during Part A. All participants received patiromer during Part A; Part B participants were randomized to continue patiromer or switch to placebo. Total study participation was up to 14 weeks (including up to 2 weeks of follow up). The dose of patiromer could be titrated based on participant's serum potassium response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05422755 -
The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients
|
||
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Recruiting |
NCT04064827 -
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02218099 -
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02276742 -
Lifestyle Management of CKD in Obese Diabetic Patients
|
N/A | |
| Completed |
NCT01222234 -
Impact of Vitamin D Therapies on Chronic Kidney Disease
|
N/A | |
| Recruiting |
NCT05106387 -
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
|
||
| Completed |
NCT05373303 -
The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®
|
N/A | |
| Completed |
NCT01247311 -
Vitamin D and the Health of Blood Vessels in Kidney Disease
|
N/A | |
| Completed |
NCT04042350 -
Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
|
||
| Completed |
NCT02733328 -
Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
|
||
| Completed |
NCT02341664 -
Patient and Provider Assessment of Lipid Management Registry
|
||
| Enrolling by invitation |
NCT06322641 -
A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
|
||
| Completed |
NCT05755373 -
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
|
||
| Completed |
NCT02678000 -
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
|
Phase 2 | |
| Completed |
NCT02185911 -
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
|
N/A | |
| Terminated |
NCT03226899 -
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
|
Phase 4 | |
| Completed |
NCT02504294 -
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
| Active, not recruiting |
NCT04094831 -
Community-based Screening of Chronic Kidney Disease (CKD) and Measure the Impact of Health Education
|
N/A | |
| Enrolling by invitation |
NCT06447038 -
Pilot Study for the Early Detection of Chronic Kidney Disease, Non-Dialysis Objective (NDO).
|